Journal article

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon

AR krarup, M Abdel-Mohsen, MH Schleimann, L Vibholm, PA Engen, A dige, B Wittig, M Schmidt, SJ Green, A Naqib, A Keshavarzian, X Deng, R Olesen, AM Petersen, T Benfield, L Ostergaard, TA Rasmussen, J Agnholt, JR Nyengaard, A Landay Show all

Mucosal Immunology | NATURE PUBLISHING GROUP | Published : 2018

University of Melbourne Researchers

Grants

Awarded by amfAR


Awarded by Danish Council for Independent Research (DFF)


Awarded by Aarhus University Research Foundation


Awarded by NIH-National Institute of General Medical Sciences


Awarded by University of California San Francisco-Gladstone Institute of Virology and Immunology Center for AIDS Research (CFAR), an NIH


Funding Acknowledgements

We thank the trial participants. Without their efforts, this study would not have been possible. We thank Lene Svinth Johnke for her technical assistance. We also thank Dr Jacob D. Estes from the Frederick National Laboratory for Cancer Research for IHC protocols and expert advice. This study was funded by amfAR (grant number 109118), the Danish Council for Independent Research (DFF grant number 5053-00090), Aarhus University Research Foundation (AUFF-E-2016-FLS-8-9), Aarhus University, Denmark, and the NIH-National Institute of General Medical Sciences (R01GM117901). Mologen AG provided the study drug. Standards for quantitative PCR methods for tissue integrated HIV-1 DNA were made available with help from University of California San Francisco-Gladstone Institute of Virology and Immunology Center for AIDS Research (CFAR), an NIH-funded program (P30 AI027763). Centre for Stochastic Geometry and Advanced Bioimaging is supported by Villum Foundation. The funders had no role in the study design, data analyses, data interpretation or writing of the article.